All consecutive patients who newly visited the clinic of the Hayashi Eye Hospital were screened for inclusion in the study by ophthalmic technicians beginning on April 5, 2019. One eye of each patient with better corrected distance visual acuity (CDVA), or the right eye when both eyes had the same CDVA, was enrolled in the study. Eyes with an axial length greater than 26.0 mm were recruited into the high myopia group. Age- (within ±5 years) and sex-matched eyes with an axial length of 26.0 mm or less were selected to serve as controls (non-high myopia group). A total of 600 eyes of 600 patients were enrolled; 300 patients in each of the high myopia and non-high myopia groups were enrolled in six age categories (50 eyes in each age category; 25 men and 25 women): (1) 20 to 29 years, (2) 30 to 39 years, (3) 40 to 49 years, (4) 50 to 59 years, (5) 60 to 69 years, and (6) 70 to 79 years. The exclusion criteria for both groups were (1) aphakic or pseudophakic eyes; (2) eyes with corneal or optic nerve pathology; (3) eyes with clinically significant cataracts interfering with visualization of the posterior vitreous; (4) eyes with marked retinal disease around the macula, including epiretinal membrane, macular hole, vitreoretinal traction syndrome, foveoschisis, and myopic retinochoroidal atrophy; (5) patients with diabetes; (6) eyes with a history of ocular surgery or inflammation; (7) patients who refused to participate in the study; and (8) patients who had any difficulties undergoing the examinations. Eyes with abnormal PVDs characteristic of pathologic myopia, such as residual vitreous cortex after complete PVD, multiple PVDs, multilayered PVDs (vitreoschisis), and thickened vitreous cortex adhering to retinal vessels at multiple points were not excluded from the study. Patient screening was continued until 50 eyes of 50 patients (25 men and 25 women) were included in each of the six age categories for both the high myopia and non-high myopia groups; the last eye was enrolled on September 20, 2019.